Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Raw Materials (2022)

Amylyx Pharmaceuticals (AMLX) has 1 years of Raw Materials data on record, last reported at $7.2 million in Q4 2022.

  • For Q4 2022, Raw Materials changed N/A year-over-year to $7.2 million; the TTM value through Dec 2022 reached $7.2 million, changed N/A, while the annual FY2022 figure was $7.2 million, N/A changed from the prior year.
  • Raw Materials reached $7.2 million in Q4 2022 per AMLX's latest filing, up from $408000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $7.2 million in Q4 2022 and bottomed at $408000.0 in Q3 2022.